183 results
6-K
EX-99.1
BLU
Bellus Health Inc
16 Jun 23
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
4:21pm
; (d) risks relating to the Company’s ability to retain and attract key personnel during the interim period; (e) the possibility of litigation
6-K
EX-99.3
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
include giving it to the Department of Justice for civil and criminal litigation and to cities, states, the District of Columbia, and U.S. commonwealths
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
; (e) the possibility of litigation relating to the Arrangement, (f) credit, market, currency, operational, liquidity and funding risks generally … .
Securityholder Litigation
During the Pre-Closing Period, the Company shall, as promptly as possible after obtaining knowledge thereof, notify the Parent
6-K
EX-99.1
BLU
Bellus Health Inc
16 May 23
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
5:04pm
personnel during the interim period; (e) the possibility of litigation relating to the Arrangement, (f) credit, market, currency, operational, liquidity
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
):
No provision has been made in the financial statements for the resolution of the above matter. Resolution of litigation could have an effect … on the Company’s financial statements in the period that a determination is made, however, in management’s opinion, this litigation matter is not currently
6-K
EX-99.2
g6wwyttt
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
6-K
EX-99.1
rwlev3tx1itcw
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
6-K
EX-99.1
t601vk3i
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.2
tzlkmo2r jwu8b
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.1
bhqybk58b1dyqd0zrx6g
26 Apr 23
BELLUS Health Announces Meeting Updates
6:00pm
6-K
EX-99.1
pwfert3
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.1
tf4rda
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.1
m025 ja4qnk3gibuf
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
kgkw7o50e10c 8uet
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
y7r449 4lob
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
u1sdy
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
ucz8k
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
z00p 41z0rz2w3
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
3z6awfvfrsh
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
tyuxj
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm